Expo Hub
The role of FDG PET/CT in the theranostic era
About this session
Join Dr. Daniel Pryma as he takes a deep dive into the history, current uses, and the future of theranostics. Learn more about several FDA-approved theranostic pairs and discover the advantages and disadvantages of using this technology to combat life-threatening diseases.
1 / 0
Daniel A. Pyrma
University of Pennsylvania, Philadelphia, USA
Related video sessions
1 / 0
The changing prostate panorama: 18F-Fluciclovine and its role in biochemically recurrent prostate cancer
Join Dr. Hollie Lai as she discusses challenges associated with PET/CT imaging in pediatric patients. This hour-long webinar provides an in-depth review of the physiologic uptake in areas that differ from imaging adults, how to identify the differences, and what can be done to improve overall image quality when scanning pediatric patients.
The changeing prostate panorama
Join Dr. Louis Mazzarelli as he discusses the uses and benefits of 18F Fluciclovine in today’s prostate imaging landscape. Review current practice techniques, pitfalls, and a look at the future for imaging biochemically recurrent prostate cancer.
The statements by Siemens Healthineers’ customers described herein are based on results that were achieved in the customer’s unique setting. Because there is no “typical” hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.